TABLE 2.

Provider considerations for evaluating the appropriateness of single-dose AG therapy for UTI^a

Single-dose AG therapy may be appropriate

Lower tract infection (cystitis)

Local endemicity of organisms resistant to first-line UTI agents

Inpatient admission may be averted

Questionable patient adherence to oral therapy

Patient preference over oral therapy

Otherwise healthy individual

Alternative therapy recommended

Urosepsis/bacteremia

Previous infection with AG-resistant organism

High risk of Enterococcus sp. infection

Chronic renal insufficiency

Patient history of significant AG-mediated adverse drug event

^aAG, aminoglycoside; UTI, urinary tract infection.